ArticleClinical pharmacology and therapeutics2026
Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clopidogrel is first-line for secondary stroke prevention, but its effectiveness is affected by CYP2C19 genetic variation. An American Heart Association (AHA) scientific statement concluded that CYP2C19-guided P2Y12 inhibitor (P2Y12i) therapy is evidence-supported, though real-world application depends on implementation factors (e.g., timely, understandable results). This prospective observational cohort quality improvement project used data from three comprehensive stroke centers within one health system, each offering rapid CYP2C19 testing. Eligible patients had CYP2C19 testing ordered, a P2Y12i prescribed (clopidogrel or ticagrelor), or a P2Y12i indication. Consensus recommendations were clopidogrel for CYP2C19 normal/rapid/ultrarapid metabolizers (NM/RM/UM) and ticagrelor for intermediate/poor metabolizers (IM/PM). The primary target population was patients with acute ischemic stroke or TIA (AIS/TIA) prescribed a P2Y12i. The primary outcome was the proportion of discharge ticagrelor prescriptions (among P2Y12i users) with AIS/TIA, compared between IM/PM and NM/RM/UM groups. Secondary endpoints included test turnaround time (TAT), result availability before discharge, and alignment of discharge P2Y12i with consensus recommendations (PGx-aligned prescribing). The evaluation period was September 2024-August 2025. Results were available for 467 patients; 451 (97%) had results before discharge, with a median TAT of 5.2 hours (interquartile range 3.3-9.6). Of 337 patients prescribed a P2Y12i at discharge, 296 had AIS/TIA. Clinicians more often selected ticagrelor over clopidogrel for IM/PMs than NM/RM/UMs (89 of 102 [87%] vs. 11 of 194 [5.7%]; RR 15.4; 95% CI: 8.6-27.4; P < 0.0001). PGx-aligned prescribing occurred in 272 (92%) of 296 patients. Rapid CYP2C19 testing efficiently translates into tailored P2Y12i prescribing in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.